# reload+after+2024-01-22 03:44:57.447864
address1§4800 Montgomery Lane
address2§Suite 220
city§Bethesda
state§MD
zip§20814
country§United States
phone§301 500 1556
website§https://www.gaintherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
fullTimeEmployees§28
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Khalid  Islam Ph.D.', 'age': 68, 'title': 'Founder & Chairman', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 75000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthias  Alder LIC. IUR., LL.M.', 'age': 58, 'title': 'President, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 593002, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. C. Evan Ballantyne', 'age': 63, 'title': 'CFO & Secretary', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gianluca  Fuggetta', 'age': 34, 'title': 'Principal Accounting Officer & Senior Director of Corporate Reporting', 'yearBorn': 1989, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Xavier  Barril Ph.D.', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Manolo  Bellotto Ph.D.', 'age': 52, 'title': 'GM & Chief Strategy Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 251992, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joanne  Taylor Ph.D.', 'title': 'Senior VP of Research & Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Terenzio  Ignoni Pharm.D.', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.366
priceToSalesTrailing12Months§1100.9016
currency§USD
dateShortInterest§1702598400
forwardEps§-1.16
exchange§NGM
quoteType§EQUITY
shortName§Gain Therapeutics, Inc.
longName§Gain Therapeutics, Inc.
firstTradeDateEpochUtc§1616160600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b010f87c-2d85-33b5-99a7-679af46af6c6
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§6.0
targetMeanPrice§8.8
targetMedianPrice§9.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§2.14
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
